The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
05-Oct-21
$175 million
Target:
Kao Data Ltd
Acquiror:
Infratil Ltd
Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform
05-Aug-21
$2 billion
Target:
Score Media and Gaming, Inc.
Acquiror:
Penn National Gaming, Inc.
Advising the Board of Directors of Score Media and Gaming (“theScore”), a leading digital media and sports betting and technology company, regarding the acquisition of theScore by Penn National Gaming
15-Jan-21
Undisclosed
Target:
Primus Telecommunications – Subsidiary of Fusion Connect, Inc.
Acquiror:
Distributel Communications Ltd.
Advising Fusion Connect, a telecommunications services provider, on the sale of its Canadian subsidiary, Primus Telecommunications, to Distributel Communications Ltd.
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
19-Dec-19
$770 million
Target:
Wireless Infrastructure Group Limited
Acquiror:
Brookfield Asset Management
Advised 3i Infrastructure plc on the sale of Wireless Infrastructure Group Limited, a leading independent telecommunications infrastructure provider focusing on mobile towers and indoor connectivity
23-Sep-19
$NA
Target:
2Get Participações
Acquiror:
Heidrick & Struggles
Advised 2Get, the largest independent search firm in Brazil, on its sale to Heidrick & Struggles, a leading global player in executive search and consulting
19-Dec-18
$NA
Target:
Starpharma Holdings Limited, patented VivaGel BV® product
Acquiror:
ITF Pharma, US subsidiary of Italfarmaco S.p.A.
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
10-Sep-18
$100 million
Target:
Montserrat Day Hospital Group
Acquiror:
Primary Health Care
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
07-Aug-15
$NA
Target:
Victorian Thoroughbred Racing Media Rights
Acquiror:
Tabcorp Holdings Limited
Advised Tabcorp Holdings Limited (“Tabcorp”), a leading diversified Australian entertainment group with wagering, gaming, racing media and Keno operations, on reaching agreement on a long-term deal for domestic broadcast, digital and international media rights for Victorian thoroughbred racing content
08-Jun-15
$45 million
Target:
Aralez Pharmaceuticals Inc.
Acquiror:
QLT Inc.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
14-Jan-15
$309 million
Target:
Chandler Macleod Group Limited
Acquiror:
Recruit Holdings Co.,Ltd
Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Chandler Macleod Group Limited, a major general recruitment company
14-Jan-15
$55 million
Target:
Peoplebank Holdings PTY LTD
Acquiror:
Recruit Holdings Co.,Ltd
Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Peoplebank Holdings PTY LTD, Australasia’s leading IT&T recruitment company
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
18-Dec-13
$NA
Target:
Global Television
Acquiror:
NEP Group Inc.
Advised Catalyst Investment Managers on the sale of its portfolio company Global Television, Australia’s largest provider of outsourced broadcasting and video production services, to NEP Inc., a leading provider of total broadcast solutions in the US, UK and Brazil. NEP is majority-owned by private funds managed by Crestview Partners
18-Dec-13
$141 million
Target:
Open Colleges Australia Pty Ltd
Acquiror:
Apollo Education Group, Inc.
Advised Open Colleges, Australia’s leading privately owned online provider in the high-growth vocational education and training sector, on the sale of a 70% stake (plus exit arrangements for the balance) to Apollo Education Group, Inc., one of North America’s largest private education providers
31-May-13
$500 million
Target:
iSelect (30% shareholding)
Acquiror:
Ninemsn (T/A Mi9)
Advised Mi9, a joint venture between Microsoft and Nine Entertainment Co, and one of Australia’s leading digital media companies, on the sale of its 30% holding in iSelect, a leading Australian online-driven comparison service, as part of the Initial Public Offering of iSelect
15-Jan-13
$NA
Target:
Broadcast Rights for V8 Supercars
Acquiror:
Seven Network
Advised Archer Capital, a leading Australian private equity firm, and its portfolio company V8 Supercars Australia, on the sale of the Australian FTA television broadcasting rights for V8 Supercars to Seven, a leading Free to Air broadcaster in Australia
01-Nov-12
$180 million
Target:
SKY Network Television Limited
Advised Todd Corporation, a major New Zealand family office, on the divestment of its 11.1% holding in SKY Network Television Limited, New Zealand’s leading provider of pay television services
02-Sep-12
$285 million
Target:
DMG Radio Australia, a subsidiary of Daily Mail and Guardian Trust Plc
Acquiror:
Illyria Pty
Advised Daily Mail and Guardian Trust plc (DMGT), on the sale of its remaining 50% interest in its Radio business in Australia to Illyria Pty, a private investment company of Lachlan Murdoch. The Radio operations comprise two national music networks in Australia
21-Aug-12
$1.1 billion
Target:
Broadcast Rights for the National Rugby League
Acquiror:
Nine Network / Fox Sports
Advised the Australian Rugby League Commission on the sale of the Australian television broadcasting rights for the National Rugby League to Nine, a leading Free to Air broadcaster and Fox Sports, Australia’s largest pay TV broadcaster (partially owned by News Limited)
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company